CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company ...

Explore Fulcrum Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for FULC. Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending ...

‘When it comes back to a M&A perspective, we look for a cultural fit and the right customer base that fits in with our own,’ says Mark Lee, UK president of Fulcrum IT Partners. After acquiring ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end ...

Fulcrum could have earned up to $298.5 million ... and on Wednesday, March 26, at 6 PM ET, he’s revealing how to recognize when the worst is over, the trades to make before the next bull market ...

Despite a reduction in net loss year-over-year, the company reported a continued net loss of $16.6 million for Q4 2024, highlighting ongoing financial difficulties. Fulcrum plans to share clinical ...

Fulcrum Therapeutics has a 52 week low of $2.86 and a 52 week high of $13.70. The stock has a market capitalization of $193.78 million, a price-to-earnings ratio of -11.58 and a beta of 2.03.